Aktis Oncology, Inc. beat EPS estimates 31% of the time across 16 reported quarters (5 beats, 11 misses), averaging -9.1% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.44 | $-0.44 | +0.0% | Beat | |
| Q1 FY26 | $-0.31 | $-0.38 | -22.6% | Miss | |
| Q3 FY24 | $-0.10 | $-0.04 | +60.0% | Beat | |
| Q1 FY24 | $-0.12 | $-0.14 | -16.7% | Miss | |
| Q4 FY23 | $-0.18 | $-0.19 | -5.6% | Miss | |
| Q3 FY23 | $-0.18 | $-0.27 | -50.0% | Miss | |
| Q2 FY23 | $-0.16 | $-0.21 | -31.3% | Miss | |
| Q1 FY23 | $-0.18 | $-0.20 | -11.1% | Miss | |
| Q4 FY22 | $-0.25 | $-0.19 | +24.0% | Beat | |
| Q3 FY22 | $-0.20 | $-0.28 | -40.0% | Miss | |
| Q2 FY22 | $-0.19 | $-0.26 | -36.8% | Miss | |
| Q1 FY22 | $-0.22 | $-0.22 | +0.0% | Beat |
Back to AKTS overview · AKTS holders · AKTS KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.